Literature DB >> 1331281

Prostaglandins suppress VLDL secretion in primary rat hepatocyte cultures: relationships to hepatic calcium metabolism.

O G Björnsson1, J D Sparks, C E Sparks, G F Gibbons.   

Abstract

In primary cultures of rat hepatocytes, prostaglandin E2 and prostaglandin D2 (PGE2 and PGD2) inhibited the secretion of very low density lipoprotein (VLDL)-associated apoB, triacylglycerol, and cholesterol. These effects were concentration-dependent and remained apparent for at least 3 days of culture without an effect on the apoB/triacylglycerol ratio of the secreted VLDL. Prostaglandins had no effect on the overall synthesis of triacylglycerol but triacylglycerol accumulated within the cells, without intracellular accumulation of apoB. PGE2, when added to the medium together with glucagon, increased the inhibition of VLDL secretion, compared to that observed with glucagon alone. However, PGE2 did not increase the stimulatory effect of glucagon on ketogenesis. Unlike glucagon, the prostaglandins did not inhibit fatty acid synthesis nor did they stimulate ketogenesis or production of cAMP. Thus, of all the parameters of hepatic lipid metabolism studied, PGE2 and PGD2 selectively affected VLDL. Selective inhibition of VLDL secretion was also observed with the calcium antagonist verapamil. The divalent cation ionophore A23187 also inhibited VLDL release but, in contrast, also inhibited fatty acid and cholesterol synthesis. The results suggest that VLDL secretion is modulated at some optimal cell calcium concentration that may be mediated selectively by agents such as prostaglandins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331281

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

Review 1.  PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.

Authors:  Rania Nasrallah; Ramzi Hassouneh; Richard L Hébert
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

2.  Hepatic Overexpression of CD36 Improves Glycogen Homeostasis and Attenuates High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance.

Authors:  Wojciech G Garbacz; Peipei Lu; Tricia M Miller; Samuel M Poloyac; Nicholas S Eyre; Graham Mayrhofer; Meishu Xu; Songrong Ren; Wen Xie
Journal:  Mol Cell Biol       Date:  2016-10-13       Impact factor: 4.272

3.  CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice.

Authors:  Fatiha Nassir; Okunade L Adewole; Elizabeth M Brunt; Nada A Abumrad
Journal:  J Lipid Res       Date:  2013-08-20       Impact factor: 5.922

4.  Characterization of the inhibitory effects of bile acids on very-low-density lipoprotein secretion by rat hepatocytes in primary culture.

Authors:  Y Lin; R Havinga; I J Schippers; H J Verkade; R J Vonk; F Kuipers
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

5.  Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model.

Authors:  Janin Henkel; Charles Dominic Coleman; Anne Schraplau; Korinna Jöhrens; Thomas Siegfried Weiss; Wenke Jonas; Annette Schürmann; Gerhard Paul Püschel
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379

6.  Application of a dye-based mitochondrion-thermometry to determine the receptor downstream of prostaglandin E2 involved in the regulation of hepatocyte metabolism.

Authors:  Lei Shen; Tao-Rong Xie; Run-Zhou Yang; Yan Chen; Jian-Sheng Kang
Journal:  Sci Rep       Date:  2018-08-30       Impact factor: 4.379

7.  Therapeutic manipulation of gut microbiota by polysaccharides of Wolfiporia cocos reveals the contribution of the gut fungi-induced PGE2 to alcoholic hepatic steatosis.

Authors:  Shanshan Sun; Kai Wang; Li Sun; Baosong Cheng; Shanshan Qiao; Huanqin Dai; Wenyu Shi; Juncai Ma; Hongwei Liu
Journal:  Gut Microbes       Date:  2020-11-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.